Published by Benjamin Chiou on 12th February 2024
(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.
URL: http://www.digitallook.com/dl/news/story/34082589/...